SECTION 05 / DOSE RECORD
CJC-1295 doses used in published research
The microgram-per-kilogram subcutaneous doses administered in the human and animal studies — and a clear line between what was studied and what is circulated.
CJC-1295 Doses Used in Published Research
The CJC-1295 dosage record in published research is short and specific. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 ug/kg [1][3]. Teichman 2006 administered 30 or 60 ug/kg, single and multiple doses, in adults aged 21-61 [1]; Ionescu and Frohman 2006 used 60 or 90 ug/kg single doses in healthy men aged 20-40 [3]. The GHRH-knockout mouse growth study used a fixed 2 ug per dose at 24-, 48-, or 72-hour intervals [4]. Those are the doses with published outcomes attached.
A separate set of numbers circulates in community and clinic settings: fixed 100-300 ug doses for the no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin combinations [1]. Those are not derived from controlled human trials and have no published PK or safety basis [1]. This page describes research doses and the species and route in which they were studied; it does not provide human-use directions.
How much CJC-1295 should I take?
There is no established human dose. Human PK studies used single subcutaneous doses of 30, 60, or 90 ug/kg [1][3]; the "protocols" circulated online are not derived from controlled human trials [1]. This site describes research doses only, not human-use guidance. CJC-1295 is unapproved for human use anywhere, so there is no labeled dose to cite [1].
What route was used in CJC-1295 studies?
Subcutaneous injection was the primary route in the published studies [1][3]; the early GRF(1-29) pharmacokinetic work also used the intravenous route [1]. Oral bioavailability is negligible, as expected for a peptide [1]. This describes the studied route, not directions for use.
How is CJC-1295 reconstituted in research handling?
CJC-1295 is supplied as a lyophilized peptide; in research handling it is reconstituted with bacteriostatic water and refrigerated [1]. The four substitutions confer DPP-IV and protease resistance, and DAC conjugation confers the multi-day duration [2]. This is laboratory handling context, not human-use instruction.
What about CJC-1295 combined with ipamorelin?
No validated human dose exists for the combination. The CJC-1295/ipamorelin pairing rests on a two-receptor rationale — a GHRH analog plus a GH-releasing peptide — but the doses circulated online are not derived from controlled human trials of the combination [1]. The single-agent CJC-1295 PK envelope is what the literature actually measures [1].
Half-life and dosing interval
Dosing interval, in the studies that measured one, follows the half-life. Because the DAC variant's half-life is 5.8-8.1 days [1], the GHRH-knockout mouse study found once-daily 2 ug fully effective while less frequent dosing fell off progressively [4]. The short-acting no-DAC Modified GRF 1-29, by contrast, has a duration in the minutes-to-hours range, a fundamentally different interval logic [11]. The contrast between the two variants' kinetics is set out in full under DAC vs no-DAC pharmacokinetics.
Why milligram-per-kilogram framing, not fixed doses
The published human doses were scaled to body weight — 30, 60, or 90 ug/kg subcutaneously — because that is how the early-phase pharmacokinetic studies were designed [1][3]. The fixed-microgram numbers circulated in community settings (100-300 ug) are a different convention entirely, and they carry no published PK or outcome data [1]. Reporting the studied doses in their original ug/kg form keeps the record honest about what was actually administered and avoids implying that a weight-scaled research dose translates into a fixed human regimen. The two foundational studies used single doses; the multiple-dose data that produced the 28-day IGF-1 tail came from repeated weight-scaled administration in the same protocol [1].
Stability and handling context
The molecule's research handling reflects its chemistry. CJC-1295 is supplied lyophilized and, in laboratory handling, reconstituted with bacteriostatic water and refrigerated [1]. The four substitutions — D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27 — confer resistance to dipeptidylpeptidase-IV cleavage, deamidation, and oxidation, which is what gives the peptide its in-solution durability [2]. In the DAC variant, the albumin-binding moiety is what extends circulating duration after administration; it does not change the lyophilized-and-reconstituted handling [2]. Oral bioavailability is negligible, as expected for a peptide of this size [1]. None of this is human-use instruction — it is the laboratory context in which the studied material is kept.
Route as studied, not as directed
Every published dose figure on this page is tied to a route. The human pharmacokinetic studies that produced the 30, 60, and 90 ug/kg numbers used subcutaneous injection [1][3]; the earliest GRF(1-29) pharmacokinetic work also used the intravenous route before the subcutaneous DAC studies [1]. The GHRH-knockout mouse growth study used subcutaneous 2 ug doses [4]. Reporting the route alongside the dose is deliberate: a dose figure detached from its route, species, and study design is not a meaningful number, and presenting it that way would edge toward implying a protocol. The site logs what was administered, to which species, at which dose, by which route — and stops there [1].
Why no human-use dose appears here
There is no labeled dose to cite because CJC-1295 is not approved for human use anywhere [1]. For an FDA-approved drug, a dosage page could quote a labeled range as a labeled range; for an unapproved research chemical, no such reference dose exists, and the figures that circulate online are not derived from controlled human trials [1]. The 2024 FDA Pharmacy Compounding Advisory Committee reviewed the GH-secretagogue class and did not recommend CJC-1295 for the 503A compounding bulks list [1]. That regulatory status is the reason this page is a record of research doses rather than a guide to a regimen.